Mefloquine

INDICATIONS AND USAGE

Treatment of Acute Malaria Infections Mefloquine hydrochloride tablets are indicated for the treatment of mild to moderate acute malaria caused by mefloquine-susceptible strains of P. falciparum (both chloroquine-susceptible and resistant strains) or by Plasmodium vivax.

There are insufficient clinical data to document the effect of mefloquine in malaria caused by P. ovale or P. malariae.

Note:

Patients with acute P. vivax malaria, treated with mefloquine, are at high risk of relapse because mefloquine does not eliminate exoerythrocytic (hepatic phase) parasites. , primaquine). Prevention of Malaria Mefloquine hydrochloride tablets are indicated for the prophylaxis of P.

falciparum and P. vivax malaria infections, including prophylaxis of chloroquine-resistant strains of P. falciparum.

Therapy and chemoprophylaxis of malaria.

Therapy:

Mefloquine is especially indicated for therapy of P. falciparum malaria in which the pathogen has become resistant to other antimalarial agents. Following treatment of P. vivax malaria with mefloquine, relapse prophylaxis with an 8-amino-quinoline derivative, for example primaquine, should be considered in order to eliminate parasites in the hepatic phase.

Chemoprophylaxis:

Malaria chemoprophylaxis with mefloquine is particularly recommended for travellers to malarious areas in which multiply resistant P. falciparum strains occur. Official guidelines and local information on the prevalence of resistance to antimalarial drugs should be taken into consideration.

Official guidelines will normally include WHO and public health authorities. uk/diseases/malaria.

MEFLOQUINE (mefloquine tablets) is indicated for: • Prophylaxis:

Prophylaxis of P. falciparum and P. vivax malaria infections, including prophylaxis of chloroquine-resistant strains of P. falciparum. • Treatment of Acute Malaria Infections: Treatment of mild to moderate acute malaria caused by mefloquine-susceptible strains of P.

falciparum (both chloroquine- susceptible and resistant strains) or by P. vivax. 1 Pediatrics Pediatrics (< 18 years of age): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of mefloquine tablets in pediatric patients has been established.

Therefore, Health Canada has authorized an indication for pediatric use. 3 Pediatrics. Experience with mefloquine in infants less than 3 months old or weighing less than 5 kg is limited. 2 Geriatrics Geriatrics (≥ 65 years of age): Evidence from clinical studies and experience is limited in this age group.